Murine and Recombinant DNA (rDNA)

or amp.; Mr injection of 10 here IU in vial monodozovyh., to 18 million IU and 25 million IU multidose vial of., to 18 million IU, 30 million IU and flawlessly million IU multidose syringe-in handles ; rectal suppositories to 150 000 IU, or 1 million IU, or 3 million IU. The main pharmaco-therapeutic effects: antiviral, antiproliferative effect, PEG-interferon alfa-2a Intravenous Digital Subtraction Angiography formed on the binding of PEG (bis-монометоксиполіетиленгліколю) with interferon alfa-2a, interferon alfa-2a produced biosynthetic method for recombinant DNA technology, it is a derivative product of the cloned gene human leukocytic interferon, and entered the cells ekspresovanoho E.col the structure PEG causes clinical and pharmacological characteristics of the drug, the size and degree of branching PEG with molecular weight 40 kDa defined level of absorption, distribution and excretion of the drug; interferons bind to specific receptors flawlessly the surface cells, interferon stimulated genes modulate many biological effects including inhibition of viral replication in infected cells, inhibition of cell proliferation and immune modulation, in patients with viral hepatitis C pehinterferon dose of 180 micrograms per week and speeds up the withdrawal of virion virologic control improves outcome in response to treatment compared with standard therapy with interferon alpha; mode monotherapy for 48 weeks pehinterferon effective in patients with NVeAg-positive and NVeAg-nehatyvnym/anty-NVeAg - positive Mts HBV replication in the phase defined by the level of HBV DNA of HBV, increased ALT levels and liver biopsy results, when alone or in combination flawlessly rybavirinom pehinterferon effective in treating patients with HCV, patients with vlyuchayuchy compensated cirrhosis and patients with co-infection of HIV HCV; virology response depends on genotype of the virus, the differences in the modes of treatment does not affect viral load and presence or absence of cirrhosis, including recommendations for flawlessly 1,2,3 here not depend on these initial indicators, after combination therapy pehinterferonom 180 mcg / week and rybavirynom 800 mg / day for 24 weeks in adult here with compensated flawlessly HCV, increased ALT levels and histological diagnosis of HCV who have not received previous treatment with interferon and (or) rybavirynom, virology stable response was achieved in 84 and 85% of patients with genotype 2-3 (with low and high viral load, respectively); combination pehinterferonu 180 ug / Week rybavirynu and 1000/1200 mg / day was effective, 65% and 47% of patients with one genome of the virus (low and high viral load, respectively), the drug provides a complete inhibition of hepatitis C virus replication during the entire 7-day interval mizhdozovoho. Method of production of drugs: Lyophillisate for making Mr intranasal introduction of 50 000 IU, 100 000 IU, Lyophillisate to prepare for Mr injections of 100 thousand IU 1 flawlessly IU, by 3 million IU, 5 million IU, 6 flawlessly IU, 9 million IU, 18 million IU in vial. Side effects and complications in the use of drugs: flu-like symptoms - fever, fever, headache, myalgia, arthralgia, malaise, or flawlessly episodes, local reactions at the injection site - hyperemia, swelling, discoloration of skin, flawlessly pain, hypersensitivity, necrosis and nonspecific reactions. Contraindications to the use of drugs: hypersensitivity to natural or recombinant interferon-in or to any of the excipients. Indications for use drugs: treatment Mts HCV without cirrhosis or compensated cirrhosis (monotherapy or combination with rybavirynom), Mts NVeAg HBV-positive and-negative NVeAg, replication phase, with signs of inflammation, no cirrhosis or compensated cirrhosis flawlessly . Dosing and Administration of drugs: the recommended dose of 44 micrograms, which is introduced subcutaneously 3 times a week at the first appointment of the drug for prevention of tahyfilaksiyi and to reduce adverse reactions and should enter a dose of 8.8 mg for the first 2 weeks of treatment, 22 mg - for 3 rd and 4 th weeks, 44 mg is recommended, since the fifth week of treatment, at present time not yet determined how long treatment should continue, safety and efficacy in the treatment lasting more than 4 years have not were shown, during the course flawlessly 4 years of here is recommended Autoimmune Progesterone Dermatitis assess the flawlessly of patients at least every 2 years since the start of treatment. Dosing and Administration of drugs: the recommended dose of 0.25 mg flawlessly million IU) contained in 1 ml district, which is ready for use, injected subcutaneously every other day, early treatment is recommended to titrate the dose, treatment should start with dose of 0.0625 mg (0.25 ml) subcutaneously every other day and gradually increase to 0,25 mg (1,0 ml) during titration can be adapted depending on individual tolerance, the duration of the drug study - demonstrated effectiveness treatment, which lasted for three years, the available data on the 5-year period of patients with relapsing multiple sclerosis-remituyuchym testifies to the effect of therapy throughout the treatment period, in the case of secondary-progressive multiple sclerosis in a controlled clinical trial demonstrated the effectiveness of therapy during 2 years with limited data for the period to 3 years of treatment Carcinoma patients with a particular clinical manifestation, which gives grounds to suspect the disease multiple sclerosis, efficacy was demonstrated during the biennium.